
Tariffs 'could cancel out discounts with biosimilars'
Tariffs on US pharma imports could remove discounts offered to health systems by biosimilars and threaten the future of the sector, says a non-profit.
Newsletters and Deep Dive digital magazine
Tariffs on US pharma imports could remove discounts offered to health systems by biosimilars and threaten the future of the sector, says a non-profit.
A complaint against GSK alleging a major breach of the pharma industry's code of practice on prescribing information has been upheld by the PMCPA.
Access to de-identified NHS patient data by researchers based in China is not a security concern, according to UK Biobank.
During Anthropy 2025: Rebooting Britain, web editor Nicole Raleigh spoke with David Gillen, chief medical officer at Norgine.
The US has launched a national security probe into the national security implications of importing pharmaceuticals, seen as a precursor to tariffs.
Editor's Picks
Newsletters and Deep Dive
digital magazine
Editor's Picks